In the phase III ACCORD 11 trial, FOLFIRINOX was associated with the longest survival ever reported for patients with metastatic pancreatic cancer (11.1 months). However, toxicities associated with the four-drug regimen will limit its use to patients with a good performance status.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Li, J. & Saif, M. W. Advancements in the management of pancreatic cancer. JOP 10, 109–117 (2009).
Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403–2413 (1997).
Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960–1966 (2007).
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817–1825 (2011).
Mallinson, C. N. et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ. 281, 1589–1591 (1980).
Conroy, B. et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer–a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J. Clin. Oncol. 23, 1228–1236 (2005).
Saif, M. W. Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1–5, 2007. JOP 8, 365–373 (2007).
Yoo, C. et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br. J. Cancer 101, 1658–1663 (2009).
Saif, M. W. Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25–27, 2008. JOP 9, 91–98 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M. W. Saif has received honorarium as a speaker for Genentech. J. Chabot declares no competing interests.
Rights and permissions
About this article
Cite this article
Saif, M., Chabot, J. Metastatic pancreatic cancer—is FOLFIRINOX the new standard?. Nat Rev Clin Oncol 8, 452–453 (2011). https://doi.org/10.1038/nrclinonc.2011.107
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.107
